Author

Christian Agboton

CORTICOSTEROID-FREE REMISSION IN ANTI-TNF FAILED CROHN’S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB AS SECOND-LINE BIOLOGIC THERAPY: A REAL WORLD DATA REVIEW
CORTICOSTEROID-FREE REMISSION IN ANTI-TNF FAILED CROHN’S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB AS SECOND-LINE BIOLOGIC THERAPY: A REAL WORLD DATA REVIEW

Christian Agboton  et al.

COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE
COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE

OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN’S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE
OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN’S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE

Christian Agboton  et al.

COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE
COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE

Christian Agboton  et al.

MACHINE LEARNING-BASED PRECISION MEDICINE APPROACH IDENTIFIES SPECIFIC RESPONDER SUB-POPULATIONS BY DYNAMIC CLUSTERING OF PRO DATA: POST HOC ANALYSIS OF VARSITY DATASET
MACHINE LEARNING-BASED PRECISION MEDICINE APPROACH IDENTIFIES SPECIFIC RESPONDER SUB-POPULATIONS BY DYNAMIC CLUSTERING OF PRO DATA: POST HOC ANALYSIS OF VARSITY DATASET

Christian Agboton  et al.

VEDOLIZUMAB ACHIEVES CORTICOSTEROID-FREE CLINICAL RESPONSE AND REMISSION IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD META-ANALYSIS
VEDOLIZUMAB ACHIEVES CORTICOSTEROID-FREE CLINICAL RESPONSE AND REMISSION IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD META-ANALYSIS

Christian Agboton  et al.

REAL-WORLD EVIDENCE OF VEDOLIZUMAB ACHIEVING MUCOSAL HEALING AND ENDOSCOPIC IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS
REAL-WORLD EVIDENCE OF VEDOLIZUMAB ACHIEVING MUCOSAL HEALING AND ENDOSCOPIC IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS

Christian Agboton  et al.

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Christian Agboton  et al.

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA
REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Christian Agboton  et al.

Item 1 - 9 / 9
1